Contents

Search

UGT2B15 genotyping

Indications: - evaluation of the pharmacokinetics & pharmacodynamics of lorazepam & oxazepam Clinical significance: - see UDP-glucuronosyltransferase 2B15

Related

UDP-glucuronosyltransferase 2B15; UDPGT 2B15; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B8; UDPGTh-3 (UGT2B15, UGT2B8)

General

genotyping (allele testing)

References

  1. Chung JY, Cho JY, Yu KS Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94. PMID: 15961980
  2. He X, Hesse LM, Hazarika S et al Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30. PMID: 19916996 PMCID: PMC2791978 Free PMC article.